sam patrick posted an articleBiopharma research is an important source of jobs, tax revenue and research spending in SC see more
New findings show biopharma research companies a source of jobs, tax revenue and research spending in state
GREENVILLE, S.C., October 4, 2018 – This week, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report that finds there are more than 572 active clinical trials in the South Carolina, and the life science industry supports 29,500 high-quality jobs and contributes $7.9 billion to South Carolina’s economy. These clinical trials can be responsible for more than half of the $2.6 billion average cost of developing one new medicine. They are investigating some of the biggest health care challenges South Carolinians face, including arthritis, cancer, diabetes, cardiovascular disease, and Alzheimer’s disease.
The report, titled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in South Carolina,” was released at a press event held at the Westin Poinsett today, which featured a panel discussion including researchers and executives from the Greenville Health System, KIYATEC, the Hollings Cancer Center at MUSC, and the Greenwood Genetic Center, moderated by SCBIO President and CEO, Sam Konduros.
“Clinical trials offer patients novel medical treatments right here in the Palmetto State, while also allowing biopharma research organizations to innovate and grow,” said Konduros. “Across South Carolina, the life sciences and healthcare industries have had a profound impact on our economy and citizens, that continues to rapidly increase.”
Clinical trials are a vital component of bringing new life-saving drugs and treatments to market. On average, it takes approximately a decade for new medicines to go through the rigorous Food and Drug Administration (FDA) approval process. Only 12 percent of drugs successfully make it through clinical trials. Since 2004, biopharmaceutical research companies have conducted or are currently conducting more than 4,700 clinical trials in South Carolina. In 2013 alone, the nearly 1,100 active clinical trials in the state generated an estimated economic impact of $540 million.
“One of the most important things we want people to understand about medicine development is that clinical trials rely on patient participation,” said Nick McGee, Director of Public Affairs for PhRMA. “It’s incredibly important that patients are aware of ongoing trials and learn how they can help become part of finding a cure for the toughest chronic conditions and diseases we face today.”
In the United States, there are more than 7,000 open clinical trials being sponsored by the biopharmaceutical industry, universities, individuals and organizations combined. In South Carolina, of the 572 open clinical trials involving the biopharmaceutical research industry, the University of South Carolina Medial School is collaborating on more than 143 clinical trials and the Medical University of South Carolina is collaborating on more than 142.
“Many top research and medical universities call South Carolina home and are centers of innovation,” Bob Quinn, Executive Director of the South Carolina Research Authority, said. “Maintaining strong partnerships between our universities and life science companies allows us to foster developments right here in South Carolina that can then help save lives far beyond our state lines.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $71.4 billion in 2017 alone.
About SC BIO
SCBIO is South Carolina’s investor-driven public/private economic development organization focused on building, advancing, and growing the life sciences industry in the state. With an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products that make a difference across the Palmetto State and around the world. Visit us at SCBIO.org.
sam patrick posted an articleSouth Carolina Life Sciences Conference to Feature J&J Innovation Leader Michal Preminger, Over 40 National SpeakersSCBIO 2019 Conference Draws Speakers, Takes Center Stage October 29-31 see more
Conference registrations soar with sell-out expected; CEOs and top industry leaders from 30 states and countries expected in Greenville for strategic partnership development, industry insights
SOUTH CAROLINA – September 11, 2019 – Johnson & Johnson Innovation Leader Michal Preminger will join more than 40 additional national speakers at SCBIO 2019 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to South Carolina October 29-31.
Following an October 29 welcome reception showcasing downtown Greenville, Ms. Preminger will address an expected sold-out conference at the Hyatt Regency with a keynote presentation entitled “Innovation for a Better Tomorrow” as the main program gets underway the morning of October 30. Her presentation will be followed by a high-powered panel comprised of regional healthcare executives entitled “Optimizing the Future of Healthcare in SC and Beyond.”
Among other featured Conference programs are EY’s “NextWave Wellness: An Interactive View of the Future of Our Industry”, and an address by South Carolina Lieutenant Governor Pamela Evette entitled “South Carolina: Just Right for Life Sciences.” Clemson University President Jim Clements headlines Day 2 with an address entitled “The Power of Partnerships in Fueling Life Sciences”, while Medtronic global executive Christian Howell will address “Driving Value-Based Care Through Collaboration".
Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2019, with registration nearly doubling the record-setting pace of 2018. Other committed speakers and panelists include IQVIA Institute of Health Data Science SVP Murray Aitken, Innova Therapeutics CEO and Founder Robert Ryan, ChartSpan CEO & Founder Jon-MIchial Carter, Firststring Research President Dr. Gautam Ghatnekar, Nephron Pharmaceuticals CEO Lou Kennedy, USC President (Ret.) Harris Pastides, PhRMA Senior Regional Director Thomas Hardaway and numerous others. More than 20 programs will be featured over two days.
Themed “Ignite The Future!”, the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion. Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio-ag and more. Space is limited and advance registration is still available at https://www.scbio.org/cpages/register-now-for-scbio-2019.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has a $12 billion economic impact in the Palmetto State, with more than 670 firms directly involved and over 43,000 professionals employed directly or indirectly in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.
SCBIO 2019 kicks off Tuesday evening October 29 with a Grand Opening Reception for conference registrants, speakers and sponsors at Greenville’s ONE Center, presented by Prisma Health. Wednesday will feature a complete day of sessions beginning at breakfast and continuing through an evening reception presented by the Greenville Area Development Corp., Greenwood Partnership Alliance and City of Greenville. The conference will conclude Thursday at lunchtime.
“Life sciences is a major driver of South Carolina’s economy, and this conference’s growth is testament to the industry’s surging impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2019.”
Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more. All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance, Economic Development Partnership and SiMT.
As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – along with PhRMA and AdvaMed, SCBIO members include academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world. For additional information on SCBIO, visit www.SCBIO.org.